Medindia

X

Rosa & Co. to Present Research Results at the 2016 Society for Neuroscience Annual Meeting

Thursday, November 10, 2016 Research News J E 4
Advertisement

SAN CARLOS, Calif., Nov. 10, 2016 /PRNewswire/ -- Rosa & Co. LLC, the worldwide commercial leader in PhysioPD™ Research, today announced their participation and poster presentation at the 2016 Society for Neuroscience Annual Meeting to be held in San Diego, CA on November 12-16, 2016.  The conference will bring together renowned neuroscientists and experts in the field of neuroscience to discover new information and get acquainted with the latest research.

Logo - http://photos.prnewswire.com/prnh/20161110/437794LOGO

Dr. Christina Friedrich, Rosa's Chief Engineer, PhysioPD, will present a poster entitled "A Quantitative Systems Pharmacology Platform of Brain and Serum Progranulin (PGRN) to Investigate Targets in Frontotemporal Dementia (FTD)" on Monday, November 14, 2016 from 8:00 am - 12:00 pm.  The poster will demonstrate how a PGRN PhysioPD Research Platform has been used to improve understanding of PGRN production dynamics, generate new hypotheses to explain conflicting data, and evaluate the potential effects of modulating different targets and drug effects on increasing PGRN for the treatment of FTD.

PhysioPD, Rosa's brand of Quantitative Systems Pharmacology (QSP), is a proven and powerful research approach that enables unique scientific insight and informs decisions from early discovery through clinical development. The most innovative R&D organizations in the industry are increasingly adopting PhysioPD Research as an essential research component for more informed decision-making. Rosa's participation in this conference further demonstrates its commitment to expanding the adoption of PhysioPD  into a standard research method used within the pharmaceutical industry.

"We are pleased to share the groundbreaking work from our PhysioPD Research and are honored that Dr. Friedrich's presentation was accepted for inclusion in the Society for Neuroscience meeting."

-Dr. Ron Beaver, Founder & CEO, Rosa & Co. LLC

About Rosa Rosa supports clients with their significant research decisions – from preclinical through clinical development – by creating and utilizing customized PhysioPD™ Research Platforms to elucidate the connection between drug and disease mechanisms and ultimate patient outcomes. The PhysioPD Platforms are used to research and simulate normal and disease physiology, drug action, patient variability, and trial outcomes. Rosa's clients are involved in Platform creation, qualification, and biological simulation research. Clients retain the PhysioPD Platforms to support future research and program decisions. Rosa's staff has unparalleled professional experience applying biological modeling and simulation research to support drug development and has over 13 years of client engagements in virtually all therapeutic areas. Rosa is unique in its breadth and depth of therapeutic area experience, including metabolism, immuno-oncology, oncology, cardiovascular, inflammation, immune dysfunction, central nervous system, dermatology, rare disease and antibacterial/antiviral biology. For more information, visit http://www.rosaandco.com/news.html.

Rosa, the Rosa logo, and PhysioMap are registered trademarks and PhysioPD is a trademark of Rosa & Co. LLC.

Media Contact:Stephanie Sherman425-591-5738 132916@email4pr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rosa--co-to-present-research-results-at-the-2016-society-for-neuroscience-annual-meeting-300360624.html

SOURCE Rosa & Co.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Alabama Tele-Mammography Group Selects Sectra as i...
S
Molecular Diagnostics Market Worth USD 11.04 Billi...